№ lp_2_1_15650
Official MassHealth policy bulletin detailing additions to the MassHealth Drug List and revisions to prior authorization requirements and brand preference status effective August 9, 2021.
Number: 169
Date: August 5, 2021
Effective Date: August 9, 2021
Program: MassHealth
Document Type: Drug List Update Bulletin
Subject: Updates to the MassHealth Drug List (MHDL)
Region: Massachusetts
Issuing Organization: MassHealth
Content Focus: Additions of newly marketed drugs; changes in prior authorization requirements; updates to Brand Name Preferred Over Generic Drug List
Drugs Added: Abecma (idecabtagene vicleucel); Amondys 45 (casimersen); Bronchitol (mannitol inhalation powder); Evkeeza (evinacumab-dgnb); Exservan (riluzole film); Fotivda (tivozanib); Nulibry (fosdenopterin); Pepaxto (melphalan flufenamide); Reditrex (methotrexate subcutaneous injection); ursodiol 200 mg, 400 mg capsule; Vesicare LS (solifenacin suspension); Zegalogue (dasiglucagon)
Policy Changes: Modifications to prior authorization status for specified antifungal, corticosteroid, inhaled respiratory, and gabapentinoid agents
Related List: MassHealth Brand Name Preferred Over Generic Drug List
Administrative Notes: Definitions of PA, BP, CO, PD designations and coverage conditions
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.